Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer Intervention:   Drug: Nivolumab Sponsors:   Seoul National University Hospital;   Seoul National University Bundang Hospital;   Korean Cancer Study Group (KCSG);   Eisai Korea;   Ono pharmaceutical Korea Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials